Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0001613103
$96.59
+3.83% · delayed ~15 min
Last price from Oct 22, 2026
$123.65B market value
From Medtronic plc's FY2026 10-K, filed Jun 18, 2026 · read the filing
Medtronic makes medical devices and equipment. It took in $36.36B last year, which makes it a large company. Of every dollar it sells, about 13 cents is left as profit.
The financial picture is led by profitability and accounting, with growth and debt worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by KIIL HARRY SKIP, not under a pre-arranged plan.
$138.9K sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From Medtronic plc's FY2026 annual filing · share price scored separately
Largest year-over-year changes in FY2026
Revenue
$33.54B → $36.36B
Gross profit
$21.91B → $23.64B
Operating income
$5.96B → $6.47B
Cash
$2.22B → $1.95B
Measured against FY2025, from the 10-K filed Jun 18, 2026
Improved: +8.4%
$33.54B to $36.36BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
How the latest move compares (quote delayed ~15 min), and what was published around it
MDT rose 3.83% on the latest quote. The average Health Care company tracked here moved +1.56%, and the S&P 500 −1.04%. That is 2.3 points above its sector and 4.9 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 10% a year for the next 10 years. Over the last 10 years it grew by about 3% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 13 cents of every dollar of sales as profit, earning $4.80B last year.
Slowly. Sales grew 8.4% last year.
Manageable, but notable. Clearing its debt would take about 3.5 years of cash flow. For every $1 it owes, it owns $2.17 in assets.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 76 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 50% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2026 annual filing
Last year it earned $4.80B and generated $7.33B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202610-K · Jun 18, 2026Filing for FY2026 | FY202510-K · Jun 20, 2025Filing for FY2025 | FY202410-K · Jun 20, 2024Filing for FY2024 | FY202310-K · Jun 22, 2023Filing for FY2023 | FY202210-K · Jun 23, 2022Filing for FY2022 | ChangeFY2026 vs FY2025 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B | +8.4% |
| Cost of revenue | $12.72B | $11.63B | $11.22B | $10.72B | $10.14B | +9.4% |
| Gross profit | $23.64B† | $21.91B† | $21.15B† | $20.51B† | $21.54B† | +7.9% |
| Gross marginGross profit ÷ revenueWhat is this? | 65.0% | 65.3% | 65.3% | 65.7% | 68.0% | −0.3 pts |
| Selling, general and administrative | $11.78B | $10.85B | $10.74B | $10.41B | $10.29B | +8.6% |
| Operating income | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B | +8.6% |
| Operating marginOperating income ÷ revenueWhat is this? | 17.8% | 17.8% | 15.9% | 17.6% | 18.2% | +0.0 pts |
| Interest expense | $715.0M | $729.0M | $719.0M | $636.0M | $553.0M | −1.9% |
| Income before tax | $6.14B | $5.63B | $4.84B | $5.36B | $5.52B | +9.0% |
| Net income | $4.80B | $4.66B | $3.68B | $3.76B | $5.04B | +3.0% |
| Net marginNet income ÷ revenueWhat is this? | 13.2% | 13.9% | 11.4% | 12.0% | 15.9% | −0.7 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $3.75 | $3.64 | $2.80 | $2.82 | $3.79 | +3.1% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
Others in the same industry
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Reported another kind of transaction — 182 shares
Holds 9,977 shares after this filing.
Reported another kind of transaction — 252,813,348 shares
Holds 0 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Had a director or senior officer leave or join · Held a shareholder vote · Made a Regulation FD disclosure
Read the filingReported another event
Read the filingWrite down why you are following Medtronic plc, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 365 subsidiaries named in its 10-K, incorporated across 84 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from MDT's 10-K for fiscal year 2026 (period ending 2026-04-24, filed Jun 18, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2026 | 8.0 | 7/9 | 10-K, filed Jun 18, 2026 |
| FY2025 | 8.0 | 6/9 | 10-K, filed Jun 20, 2025 |
| FY2024 | 8.0 | 6/9 | 10-K, filed Jun 20, 2024 |
| FY2023 | 7.0 | 5/9 | 10-K, filed Jun 22, 2023 |
| FY2022 | 9.0 | 8/9 | 10-K, filed Jun 23, 2022 |
| FY2021 | 8.0 | 6/9 | 10-K, filed Jun 25, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
7 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
3.01
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.58
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2026 filing as filed with the SEC.
Improved: +7.9%
$21.91B to $23.64BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +8.6%
$5.96B to $6.47BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -12.1%
$2.22B to $1.95BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Q1 FY2027 against Q1 FY2026, from the 10-Q filed Sep 3, 2026 — read it.
Improved: +41.3%
$1.04B to $1.47BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +120.9%
$584.0M to $1.29BCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: +41.5%
$0.81 to $1.15Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +22.1%
$1.45B to $1.76BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +32.8%
$1.27B to $1.69BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +13.7%
$8.58B to $9.76BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +13.7%
$5.58B to $6.34BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +1.2 pts
16.8% to 18.1%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +2.9 pts
12.1% to 15.1%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
10 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 8% and 12%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 33 analysts covering this company, as of . Their views, not this site's.
Of 33 analysts publishing on this company, 9 say strong buy, 13 say buy and 11 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 3.1% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 24.6x — investors pay $24.6 for each $1 of trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
Sold on the open market — 50,000 shares at $95.00 ($4.8M)
Holds 277,866 shares after this filing.
Sold on the open market — 10,420 shares at $96.00 ($1.0M)
Holds 105,916 shares after this filing.
Sold on the open market — 1,483 shares at $93.65 ($138.9K)
Holds 42,186 shares after this filing.
Gifted shares — 600 shares
Holds 16,398 shares after this filing.
Had shares withheld to cover taxes — 1,084 shares at $92.30 ($100.1K)
Holds 116,336 shares after this filing.
Had shares withheld to cover taxes — 212 shares at $85.39 ($18.1K)
Holds 14,661 shares after this filing.
Was granted or awarded shares — 2,337 shares
Holds 16,998 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 50,000 shares ($4.8M) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 10,420 shares ($1.0M) on or after .
Shares originally obtained via ESPP Purchase.
Filed notice to sell 1,483 shares ($138.9K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 3,102 shares ($257.9K) on or after .
Shares originally obtained via ESPP Purchase.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Quarterly report for Q1 FY2027
Revenue +13.7% · Operating margin +1.2 pts · Profit +41.3% — against Q1 FY2026
Published results
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2026
Revenue +8.4% · Gross profit +7.9% · Operating income +8.6% — against FY2025
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingMade a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2026
Revenue +8.7% · Operating margin −3.6 pts · Long-term debt +16.2% — against Q3 FY2025
Read the filingPublished results
Read the filingQuarterly report for Q2 FY2026
Revenue +6.6% · Gross profit +8.1% · Operating income +5.7% — against Q2 FY2025
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingAmended its charter or changed its financial year · Held a shareholder vote
Read the filingSigned a material agreement · Reported another event
Read the filingMade a Regulation FD disclosure · Reported another event
Read the filingQuarterly report for Q1 FY2026
Revenue +8.4% · Profit margin −1.0 pts · Free cash flow +25.3% — against Q1 FY2025
Read the filingProxy statement for a shareholder meeting
Read the filingThe first 40 of 365. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-06-18. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Global Intrathecal Pump Market Size, Share, Trends, and Forecast, 2026-2032 | Aging Demand and Longer-Life Devices Support a $360 Million Market by 2032
Yahoo Finance ·
Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026
Yahoo Finance ·
Global Medical Devices Market Size, Share, and Growth Forecast to 2031 | Aging Populations Push the Global Medical Devices Market Toward $818 Billion
Yahoo Finance ·
Medtronic (MDT) Shares Moved, So What Is Driving Attention Now?
Yahoo Finance ·
Medtronic’s next-gen pacemaker portfolio secures CE mark
Yahoo Finance ·
U.S. Wireless Cardiac Monitoring Systems Market Size, Share, and Forecast 2026-2033 Featuring Profiles of Philips, iRhythm Technologies, Abbott, Medtronic, Biotronik (Teleflex) and More
Yahoo Finance ·
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Yahoo Finance ·
Is Johnson & Johnson Stock Ready For A MedTech Stall?
Yahoo Finance ·
Can Boston Scientific Stock Jump 30%?
Yahoo Finance ·
How Has Intuitive Surgical's Story Changed?
Yahoo Finance ·
Can Boston Scientific Stock Bounce Off This Support Again?
Yahoo Finance ·
Intuitive Surgical Stock Slides Despite Earnings Beat as Company Discloses Settlement
Yahoo Finance ·
Primary sources and further research